Filing Details
- Accession Number:
- 0001127602-24-028301
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-12-02 16:26:06
- Reporting Period:
- 2024-11-27
- Accepted Time:
- 2024-12-02 16:26:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1682852 | Moderna Inc. | MRNA | Biological Products, (No Disgnostic Substances) (2836) | 813467528 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1736359 | M James Mock | 325 Binney Street Cambridge MA 02142 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-11-27 | 1,326 | $0.00 | 10,831 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-11-27 | 329 | $0.00 | 11,160 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-11-27 | 1,326 | $0.00 | 12,486 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-11-29 | 1,420 | $42.79 | 11,066 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Performance Stock Units | Disposition | 2024-11-27 | 1,326 | $0.00 | 1,326 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2024-11-27 | 329 | $0.00 | 329 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2024-11-27 | 1,326 | $0.00 | 1,326 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1,326 | No | 4 | M | Direct | ||
| 2,959 | No | 4 | M | Direct | ||
| 1,326 | No | 4 | M | Direct |
Footnotes
- Performance stock units convert into common stock on a one-for-one basis.
- Restricted stock units convert into common stock on a one-for-one basis.
- Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs and PSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent a discretionary trade by the Reporting Person.
- 25% of the shares subject to this performance stock unit award vested on May 31, 2024 upon determination of achievement of the performance criteria, with the remainder vesting in three (3) equal installments on August 27, 2024, November 27, 2024 and February 27, 2025.
- 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
- 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter.
Billionaire Hedge Funds
